CD279 (PD1), Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-CD279 (PD1), Mouse antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | CD279 (PD1), Mouse |
| Clone | HA2-7B1 |
| Host Species | Rat |
| Reactive Species | mouse |
| Isotype | IgG2b |
| Format | fluorescein (FITC) conjugate |
| Size | 9 µg in 300 µL |
| Concentration | 1:10 |
| Applications | Flow cytometry, MICS (MACSima Imaging Cyclic Staining), Immunofluorescence, Immunohistochemistry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | CD279 (PD1) Antibody, anti-mouse, FITC. CD279 (PD1) is a 55 kDa member of the Ig superfamily expressed mainly on activated T and B lymphocytes. Expression is induced on activated myeloid cells as well. CD279 (PD1) is thought to be involved in lymphocyte clonal selection and plays a key role in peripheral tolerance and autoimmune disease in mice. The ligands of CD279 (PD1), PD-L1 (B7-H1) and PD-L2 (B7-DC), belong to the B7 immunoglobulin superfamily. Clone HA2-7B1 has been used to block the binding of PD1 to its ligands. |
| Immunogen | n/a |
| Other Names | PDCD1, Ly101, PD1, Pdc1 |
| Gene, Accession # | Gene ID: 18566 |
| Catalog # | 130-102-973 |
| Price | $31 |
| Order / More Info | CD279 (PD1), Mouse Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Tsushima, F. et al. (2007) Interaction between B7-H1 and PD-1 determines initiation and reversal of T cell anergy. Blood 110: 180-185. | Salama, A. D. et al. (2003) Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198: 71-78. | Iwai, Y. et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99: 12293-12297. | Hirano, F. et al. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunitiy. Cancer Res. 65: 1089-1096. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies